TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07457918: Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Sponsor: Verrica Pharmaceuticals Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 250 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,310,056

Rescue Site Savings

+$1,508,608

Unlock Full NCT07457918 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07457918 Rescue Dossier →